Stockscreener 앱 받기
11.19
4.28%
-0.50
시간 외 거래:
11.19
전일 마감가:
$11.69
열려 있는:
$11.51
하루 거래량:
597.06K
Relative Volume:
1.47
시가총액:
$386.30M
수익:
$90.44M
순이익/손실:
$561.00K
주가수익비율:
1,865.00
EPS:
0.006
순현금흐름:
$19.19M
1주 성능:
+8.33%
1개월 성능:
-2.53%
6개월 성능:
+12.80%
1년 성능:
-30.97%
1일 변동 폭
$11.16
$11.79
1주일 범위
$10.35
$12.17
52주 변동 폭
$8.12
$16.44
Delcath Systems Inc Stock (DCTH) Company Profile
명칭
Delcath Systems Inc
전화
(518) 743-8892
주소
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
11.19 | 403.56M | 90.44M | 561.00K | 19.19M | 0.006 |
ABT
Abbott Laboratories
|
89.13 | 158.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 120.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 105.25B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 72.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 50.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Craig Hallum | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2022-07-26 | 재개 | Canaccord Genuity | Buy |
| 2021-12-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Canaccord Genuity | Buy |
| 2021-01-05 | 개시 | BTIG Research | Buy |
| 2020-06-01 | 개시 | Laidlaw | Buy |
모두보기
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Delcath Systems, Inc. - MLQ.ai
Delcath Systems, Inc. Stock 12‑Month Price Target Cut to $20.83, Implies 95% Upside - TradingView
European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan
Delcath therapy included in European uveal melanoma guidelines - Investing.com
FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC - Quantisnow
(DCTH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Abbott’s $21bn Bet on Exact Sciences Takes Center Stage at ASCO 2026 - Citeline News & Insights
Delcath Systems Q1 2026 Earnings: Narrowed Loss Surprises, Stock AdvancesCore Business Growth - newsline.com
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - BioSpace
Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts - Moomoo
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Q1 2026 Delcath Systems Inc Earnings Call Transcript - GuruFocus
DCTH Q1 2026 Earnings: Narrower-Than-Expected Loss Bolstered by Cost DisciplineEarnings Beat Alert - The Legal Advocate
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued - GuruFocus
Delcath Systems announces inducement grants - Medical Buyer
How (DCTH) Movements Inform Risk Allocation Models - Stock Traders Daily
Implied volatility surging for Delcath Systems stock options - MSN
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Tribune News
Delcath Systems announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
New Delcath hires receive 24,500 stock units over 3 years - Stock Titan
Dental EconomicsDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Delcath Systems (DCTH) director receives grant of 22,500 stock options at $11.61 - Stock Titan
Delcath Systems (NASDAQ: DCTH) director receives 22,500 stock options at $11.61 strike - Stock Titan
Delcath Systems (DCTH) director awarded 22,500 stock options at $11.61 - Stock Titan
Director at Delcath (NASDAQ: DCTH) awarded 22,500 stock options - Stock Titan
Delcath (DCTH) awards director 22,500 options at $11.61 strike - Stock Titan
Delcath Systems, Inc. 8-K Filing May 13, 2026 – Company Information, Equity Incentive Plan, and SEC Compliance 212 - Minichart
Delcath Shareholders Approve Expanded Equity Plan and Governance - TipRanks
Delcath Systems shareholders approve equity plan amendment and board elections - Investing.com Nigeria
Delcath Systems shareholders approve equity plan amendment and board elections By Investing.com - Investing.com South Africa
Delcath (NASDAQ: DCTH) approves 1.8M-share boost to 2020 equity plan - Stock Titan
Earnings call transcript: Delcath Systems Q1 2026 beats EPS forecast, stock rises - Investing.com Nigeria
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference - Yahoo Finance
TradingKey - TradingKey
Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep Dive - AlphaStreet
Tangible book value per share of Delcath Systems, Inc. – SWB:DV3R - TradingView
Delcath Systems Balances Growth with Rising Costs - The Globe and Mail
MSN Money - MSN
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Delcath Systems, Inc. (NASDAQ:DCTH) Q1 2026 Earnings Call Transcript - Insider Monkey
Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results - MarketBeat
Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector - DirectorsTalk Interviews
Uveal Melanoma Treatment Market is expected to Hit US$ 2.7 - openPR.com
Delcath Systems Reports First Quarter 2026 Results and Business Highlights - BioSpace
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 - BioSpace
Number of shareholders of Delcath Systems, Inc. – DUS:DV3R - TradingView
Delcath Systems, Inc. (DCTH) reports Q1 loss, misses revenue estimates - MSN
Delcath Systems Q1 Earnings Call Highlights - MarketBeat
Delcath Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Delcath Systems Inc (DCTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Delcath Systems Inc 주식 (DCTH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sylvester John Richard | Director |
Nov 21 '25 |
Buy |
8.89 |
4,386 |
38,992 |
14,936 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER |
Jun 12 '25 |
Option Exercise |
4.78 |
42,000 |
200,760 |
168,882 |
1.63%
자본화:
|
볼륨(24시간):